Abatacept in B7-1-positive proteinuric kidney disease.
Abatacept in B7-1-positive proteinuric kidney disease.
复制标题
DOI：
10.1056/nejmoa1304572
复制
发表时间：
2013-12-19
期刊：
影响因子：
--
通讯作者：
Mundel P
中科院分区：
文献类型：
--
作者：
Yu CC;Fornoni A;Weins A;Hakroush S;Maiguel D;Sageshima J;Chen L;Ciancio G;Faridi MH;Behr D;Campbell KN;Chang JM;Chen HC;Oh J;Faul C;Arnaout MA;Fiorina P;Gupta V;Greka A;Burke GW 3rd;Mundel P
阿巴西普（细胞毒性 T 淋巴细胞相关抗原 4-免疫球蛋白融合蛋白 [CTLA-4-Ig]）是一种靶向 B7-1 (CD80) 的共刺激抑制剂。本报告描述了 5 名患有局灶节段性肾小球硬化症 (FSGS) 的患者（其中 4 名患者移植后复发 FSGS，1 名患者原发性 FSGS），肾活检标本中足细胞 B7-1 免疫染色显示蛋白尿。阿巴西普诱导这些患者的蛋白尿部分或完全缓解，表明 B7-1 可能是治疗某些肾小球病的有用生物标志物。我们的数据表明，阿巴西普可以稳定足细胞中 β1-整合素的激活，并减少 B7-1 阳性肾小球疾病患者的蛋白尿。
Abatacept (cytotoxic T-lymphocyte–associated antigen 4–immunoglobulin fusion protein [CTLA-4–Ig]) is a costimulatory inhibitor that targets B7-1 (CD80). The present report describes five patients who had focal segmental glomerulosclerosis (FSGS) (four with recurrent FSGS after transplantation and one with primary FSGS) and proteinuria with B7-1 immunostaining of podocytes in kidney-biopsy specimens. Abatacept induced partial or complete remissions of proteinuria in these patients, suggesting that B7-1 may be a useful biomarker for the treatment of some glomerulopathies. Our data indicate that abatacept may stabilize β1-integrin activation in podocytes and reduce proteinuria in patients with B7-1–positive glomerular disease.